5-methoxy-3-[1-(4,5,6,7-tetrahydro-1H-indol-2-yl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one | 1126899-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-methoxy-3-[1-(4,5,6,7-tetrahydro-1H-indol-2-yl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one
• 英文别名: (3Z)-5-methoxy-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indol-2-one
• CAS: 1126899-12-4
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.353
• InChiKey: NJAYBLLXJGHMSQ-DHDCSXOGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• BioMarkers for the Progression of Alzheimer's Disease
  申请人：He Yunsheng

  公开号：US20100035251A1

  公开（公告）日：2010-02-11

  The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression.